Gemini Therapeutics has completed $42.5 million in Series A financing, according to a company press release.
Co-led by Atlas Venture, Lightstone Ventures and OrbiMed, the financing is to advance multiple programs to the clinical stage, including those focused on genetically defined dry age-related macular degeneration, the release said.
“We believe the time is right to harness genetic insights into AMD, and we’ve gathered the people, the technology and the resources necessary to lead the translational effort,” James McLaughlin, Gemini CEO, president and co-founder, said in the
Uncategorized